Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00937937 · ClinicalTrials.gov registry record · Phase 2
Dinaciclib in Treating Patients With Stage IV Melanoma
A Phase 2 study of Recurrent Melanoma and Stage IV Cutaneous Melanoma AJCC v6 and v7, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 20
- Study locations
NCT00937937: Active Phase 2 study of Recurrent Melanoma and Stage IV Cutaneous Melanoma AJCC v6 and v7, sponsored by National Cancer Institute (NCI).
NCT00937937 is a Phase 2 study of Recurrent Melanoma and Stage IV Cutaneous Melanoma AJCC v6 and v7 that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 72 participants, below the 170-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00937937, a Phase 2 study of Recurrent Melanoma and Stage IV Cutaneous Melanoma AJCC v6 and v7, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial is studying the side effects and how well dinaciclib works in treating patients with stage IV melanoma. Dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
From date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact.
Conditions Studied
Interventions
- DRUG Dinaciclib
Study Locations (20)
California
- East Bay Radiation Oncology Center - Castro Valley
- Eden Hospital Medical Center - Castro Valley
- Valley Medical Oncology Consultants-Castro Valley - Castro Valley
- Bay Area Breast Surgeons Inc - Emeryville
- Valley Medical Oncology Consultants-Fremont - Fremont
- Contra Costa Regional Medical Center - Martinez
- El Camino Hospital - Mountain View
- Wilma Chan Highland Hospital - Oakland
- Alta Bates Summit Medical Center - Summit Campus - Oakland
- Bay Area Tumor Institute - Oakland
- Hematology and Oncology Associates-Oakland - Oakland
- Tom K Lee Inc - Oakland
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
- Valley Care Health System - Pleasanton - Pleasanton
- Valley Medical Oncology Consultants - Pleasanton
- Doctors Medical Center- JC Robinson Regional Cancer Center - San Pablo
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- University of Arkansas for Medical Sciences - Little Rock
- Highlands Oncology Group - Rogers - Rogers
Alabama
- Providence Hospital - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2009-07-01 |
| Est. Completion | 2026-03-19 |
| Phase | Phase 2 |
What the registry record for NCT00937937 still lists
NCT00937937 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 170-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (58% lower).
The record links to 7 conditions, with Recurrent Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Dinaciclib is the first listed.
NCT00937937 names 20 study sites across 3 states, led by California, Arkansas, Alabama.
Frequently Asked Questions
What is clinical trial NCT00937937 about?
NCT00937937 is a clinical study titled "Dinaciclib in Treating Patients With Stage IV Melanoma". This phase II trial is studying the side effects and how well dinaciclib works in treating patients with stage IV melanoma. Dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT00937937?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2009-07-01. Estimated completion is 2026-03-19.
What conditions does trial NCT00937937 study?
This clinical trial studies the following conditions: Recurrent Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Mucosal Melanoma, Acral Lentiginous Melanoma, Cutaneous Nodular Melanoma.
What interventions are being tested in trial NCT00937937?
The interventions under investigation include: Dinaciclib (DRUG).
Who is sponsoring clinical trial NCT00937937?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00937937 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00937937's enrollment target sits among peer trials
72 8th of 23 higher than 16 of 23 other Recurrent Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
COMPLETED · Phase 2
-
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
COMPLETED · Phase 2
-
Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI